Actively Recruiting
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants
Led by Celgene · Updated on 2025-12-24
42
Participants Needed
1
Research Sites
25 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the effect of Itraconazole and Rifampin on the drug levels of AR-LDD (BMS-986365) in healthy adult male participants.
CONDITIONS
Official Title
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male participants aged 18 to 60 years at the time of signing consent
- Body Mass Index (BMI) between 18.0 and 32.0 kg/m2
- Healthy as determined by medical history, physical exam, vital signs, 12-lead ECG, transthoracic echocardiogram, and lab tests
You will not qualify if you...
- Presence of any significant or chronic illness
- History of heart failure, ischemic heart disease, serious cardiac arrhythmias, or prolonged QT interval
- Other protocol-defined inclusion/exclusion criteria apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Syneos Health Clinic
Miami, Florida, United States, 33136
Actively Recruiting
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
F
First line of the email MUST contain the NCT# and Site #.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here